Citations

Showing 10 of 108119 citations.

Application of Color Doppler Ultrasound to Identify and Repair Postoperative Cerebrospinal Fluid Leak: A Technical Note
West, James L., Abode-Iyamah, Kingsley, Chen, Selby G., Fox, W. Christopher, Bydon, Mohamad, Miller, David A., Clendenen, Steven R., West, James L., Abode-Iyamah, Kingsley, Chen, Selby G., Fox, W. Christopher, Bydon, Mohamad, Miller, David A., Clendenen, Steven R.

Mayo Clinic

Operative Neurosurgery | December 15, 2021 | Volume: 22 | Issue: 1 | Pages: e12-e17

10.1227/ons.0000000000000007 | PMID 34982905 Get It

BACKGROUND: Incidental durotomy is a known complication of spinal surgery. Persistent cerebrospinal fluid (CSF) leak after unrecognized durotomy may lead to prolonged hospitalization and significant morbidity. If initial bed rest fails, the surgeon must choose between nontargeted methods such as oversewing the wound and lumbar drain placement or return to the operating room. OBJECTIVE: To report the novel use of color flow doppler (CFD) in conjunction with ultrasound (US) to localize the point of CSF leak, assist with aspiration of the pseudomeningocele, and direct the application of fibrin sealant or epidural blood patch. METHODS: This article includes a description of the technique as a technical note. RESULTS: A 72-year-old man underwent L2-5 laminectomies for spinal stenosis. During the index operation, a durotomy occurred and was repaired primarily. The patient subsequently developed leg weakness, back pain, and bulging of the incision. Using CFD, the site of durotomy was determined. Under direct visualization, 34 mL of CSF was aspirated from the pseudomeningocele and 20 mL of fibrin sealant was placed opposing the durotomy. At 2-month follow-up, CFD confirmed absent flow and MRI demonstrated pseudomeningocele resolution. CONCLUSION: This article represents the first report highlighting the utility of CFD US to guide epidural patch placement for postsurgical CSF leaks. CFD allows localization of the durotomy and direct application of blood or fibrin sealant, potentially increasing the success rate of epidural blood patch in postoperative patients. This approach is less invasive than revision surgery and does not require the prolonged hospitalization of lumbar drainage or other nontargeted interventions.
NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
Wen, Ti , Barham, Whitney , Li, Ying , Zhang, Henan , Gicobi, Joanina K. , Hirdler, Jacob B. , Liu, Xin , Ham, Hyoungjun , Martinez, Kodi E. Peterson, Lavoie, Roxane R. , Monie, Dileep D. , An, Zesheng , Harrington, Susan M. , Wu, Xiaosheng , Guo, Ruifeng , Dronca, Roxana , Yan, Yiyi , Liu, Minetta C. , Vasmatzis, George , Billadeau, Daniel D. , Peterson Martinez, Kodi E, Correia, Cristina , Monie, Dileep D , Dronca, Roxana S., Mansfield, Aaron S , Yan, Yiyi , Markovic, Svetomir , Park, Sean S , Liu, Minetta , Billadeau, Daniel D , Dong, Haidong , Guo, Ruifeng , Martinez, Kodi, Lucien, Fabrice , Li, Hu , Correia, Cristina , Mansfield, Aaron S. , Markovic, Svetomir N. , Park, Sean S. , Sun, Jie , Qin, Hong , Dong, Haidong

Mayo Clinic

Cancer Immunology Research | December 15, 2021 | Volume: 10 | Issue: 2 | Pages: 162-181

10.1158/2326-6066.cir-21-0539 | PMID 34911739 Get It

Abstract Cytotoxic CD8+ T cells (CTL) are a crucial component of the immune system notable for their ability to eliminate rapidly proliferating malignant cells. However, the T-cell intrinsic factors required for human CTLs to accomplish highly efficient antitumor cytotoxicity are not well defined. By evaluating human CD8+ T cells from responders versus nonresponders to treatment with immune checkpoint inhibitors, we sought to identify key factors associated with effective CTL function. Single-cell RNA-sequencing analysis of peripheral CD8+ T cells from patients treated with anti–PD-1 therapy showed that cells from nonresponders exhibited decreased expression of the cytolytic granule-associated molecule natural killer cell granule protein-7 (NKG7). Functional assays revealed that reduced NKG7 expression altered cytolytic granule number, trafficking, and calcium release, resulting in decreased CD8+ T-cell–mediated killing of tumor cells. Transfection of T cells with NKG7 mRNA was sufficient to improve the tumor-cell killing ability of human T cells isolated from nonresponders and increase their response to anti–PD-1 or anti–PD-L1 therapy in vitro. NKG7 mRNA therapy also improved the antitumor activity of murine tumor antigen–specific CD8+ T cells in an in vivo model of adoptive cell therapy. Finally, we showed that the transcription factor ETS1 played a role in regulating NKG7 expression. Together, our results identify NKG7 as a necessary component for the cytotoxic function of CD8+ T cells and establish NKG7 as a T-cell–intrinsic therapeutic target for enhancing cancer immunotherapy. See related article by Li et al., p. 154.
Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
Tefferi, Ayalew , Gangat, Naseema , Pardanani, Animesh , Crispino, John D. , Crispino, John D

Mayo Clinic

Cancer Research | December 15, 2021 | Volume: 82 | Issue: 5 | Pages: 749-763

10.1158/0008-5472.can-21-2930 | PMID 34911786 Get It

Abstract Primary myelofibrosis (PMF) is one of three myeloproliferative neoplasms (MPN) that are morphologically and molecularly inter-related, the other two being polycythemia vera (PV) and essential thrombocythemia (ET). MPNs are characterized by JAK-STAT–activating JAK2, CALR, or MPL mutations that give rise to stem cell–derived clonal myeloproliferation, which is prone to leukemic and, in case of PV and ET, fibrotic transformation. Abnormal megakaryocyte proliferation is accompanied by bone marrow fibrosis and characterizes PMF, while the clinical phenotype is pathogenetically linked to ineffective hematopoiesis and aberrant cytokine expression. Among MPN-associated driver mutations, type 1–like CALR mutation has been associated with favorable prognosis in PMF, while ASXL1, SRSF2, U2AF1-Q157, EZH2, CBL, and K/NRAS mutations have been shown to be prognostically detrimental. Such information has enabled development of exclusively genetic (GIPSS) and clinically integrated (MIPSSv2) prognostic models that facilitate individualized treatment decisions. Allogeneic stem cell transplantation remains the only treatment modality in MF with the potential to prolong survival, whereas drug therapy, including JAK2 inhibitors, is directed mostly at the inflammatory component of the disease and is therefore palliative in nature. Similarly, disease-modifying activity remains elusive for currently available investigational drugs, while their additional value in symptom management awaits controlled confirmation. There is a need for genetic characterization of clinical observations followed by in vitro and in vivo preclinical studies that will hopefully identify therapies that target the malignant clone in MF to improve patient outcomes.
Editorial Comment
Karnes, R. Jeffrey

Mayo Clinic

Journal of Urology | December 15, 2021 | Volume: 207 | Issue: 3 | Pages: 591-591

10.1097/ju.0000000000002256.01 | PMID 34905946 Get It

On the effectiveness of integration of a rehabilitation device based on a neurointerface and neurostimulation of the spinal cord in the rehabilitation of patients with impaired upper limb movement due to neurological disorders
Ananyev, S. S., Aliev, A. G. , Shalmiev, I., Kozureva, S., Averkiev, M., Bulanov, Vladimir , Potantsev, Yu., Gerasimenko, Yu. P., Shandybina, Natalia D. , Lavrov, Igor , Moshonkina, Tatiana R. , Lebedev, Mikhail

Mayo Clinic

Materialy VIII Vserossijskoj konferencii s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka» | December 15, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34014/mpphe.2021-217-221 Get It

Millions of people around the world suffer from disorders caused by injuries and diseases of the brain and spinal cord. The combination of brain-computer interfaces and neuromodulation technologies is a new approach that could revolutionize the treatment of these disorders. In this study, we tested the effectiveness of a technique in which a patient with a spinal cord injury first undergoes spinal cord stimulation and then participates in a rehabilitation session using a brain-computer interface based on the P300 principle, which decodes visual-motor transformation and uses an assistive robot that moves the patient’s arm, and virtual reality. All healthy participants of the study were able to combine these two techniques without any undesirable effects; studies on patients with spinal cord injury are ongoing. System integration of the two methods has been already performed, and in the future, upon completion of this work, the neural interface will be able to control the stimulation parameters. We propose such integrated systems as a new approach to neurorehabilitation. Key words: brain-computer interface, neuromodulation, spinal cord stimulation, spinal cord trauma, P300, visuomotor transformation.
Lingual Raynaud's phenomenon in a patient with mixed connective tissue disease
Gilbert, Emily

Mayo Clinic

Rheumatology & Autoimmunity | December 15, 2021 | Volume: 1 | Issue: 2 | Pages: 101-103

10.1002/rai2.12011 Get It

Key points Raynaud's phenomenon may occur as a primary problem or secondary to an autoimmune disease such as scleroderma, mixed connective tissue disease, SLE, or Sjogren's. Lingual Raynaud's is rare, but it is important to recognize as it is often attributed to autoimmune disease. There is a wide range of symptoms in lingual Raynaud's from asymptomatic to severe, throbbing pain. Meticulous history taking is essential.
The prospective association between periodontal disease and brain imaging outcomes: The Atherosclerosis Risk in Communities study
Adam, Hamdi S , Lakshminarayan, Kamakshi , Wang, Wendy , Norby, Faye L. , Meyer, Katie A. , Hughes, Timothy M. , Pankow, James S. , Wong, Dean F. , Jack, Clifford R. , Lutsey, Pamela L. , Beck, Jim, Demmer, Ryan T. , Jack, Clifford R , Lutsey, Pamela L , Pankow, James S , Demmer, Ryan T , Mosley, Thomas H. , Walker, Keenan A. , Gottesman, Rebecca F. , Sen, Souvik

Mayo Clinic

Journal of Clinical Periodontology | December 15, 2021 | Volume: 49 | Issue: 4 | Pages: 322-334

10.1111/jcpe.13586 | PMID 34905804 Get It

AbstractAimWe investigate if periodontal disease is prospectively associated with cerebrovascular and neurodegenerative markers of dementia and Alzheimer's pathology.Materials and MethodsN = 1306 participants (Visit 5 mean age = 76.5 [standard deviation = 5.4] years) in the Atherosclerosis Risk in Communities study with completed dental exams at Visit 4 underwent brain magnetic resonance imaging scans at Visit 5 while N = 248 underwent positron emission tomography scans. Participants were classified as edentulous or, among the dentate, by the modified Periodontal Profile Class. Brain volumes were regressed on periodontal status in linear regressions. Cerebrovascular measures and β‐amyloid positivity were regressed on periodontal status in logistic regressions.ResultsPeriodontal disease was not associated with brain volumes, microhaemorrhages, or elevated β‐amyloid. Compared with periodontally healthy individuals, odds ratios [95% confidence interval] for all‐type infarcts were 0.37 [0.20, 0.65] for severe tooth loss and 0.56 [0.31, 0.99] for edentulous participants.ConclusionsWithin the limitations of this study, periodontal disease was not associated with altered brain volumes, microhaemorrhages, or β‐amyloid positivity. Tooth loss was associated with lower odds of cerebral infarcts.
Abdominal Wall Vascularized Composite Allotransplantation: A Scoping Review
Bustos, Valeria P. , Escandón, Joseph M. , Santamaría, Eric , Ciudad, Pedro , Forte, Antonio J. , Leckenby, Jonathan I. , Langstein, Howard N. , Manrique, Oscar J. , Forte, Antonio Jorge , Escandón, Joseph M

Mayo Clinic

Journal of Reconstructive Microsurgery | December 15, 2021 | Volume: 38 | Issue: 06 | Pages: 481-490

10.1055/s-0041-1740121 | PMID 34905782 Get It

AbstractBackground Abdominal wall vascularized composite allotransplantation (AW-VCA) is a novel reconstructive technique used for large abdominal wall defects in combination with intestinal transplantation (ITx) or multivisceral abdominal transplantation (MVTx). Since the introduction of this procedure, several studies have been published reporting their experience. This study aims to present a scoping review looking at all available evidence-based medicine information to understand the most current surgical techniques and clinical outcomes.Methods This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) extension for scoping reviews checklist. A comprehensive research strategy of several databases was conducted.Results A total of 31 studies were included in this review, which comprised animal, cadaveric, and human studies. In human studies, four surgical techniques with high flap survival rates and low complication rates were found. In cadaveric studies, it was shown that the use of iliofemoral cuff-based flaps provided adequate tissue perfusion to the abdominal wall graft. Also, the use of thoracolumbar nerves have been described to provide functionality to the AW-VCA and prevent long-term muscle atrophy.Conclusion AW-VCA is a safe and efficient alternative for patients with large and complex abdominal wall defects. The future holds a promising evolution of a functional AW-VCA, though surgeons must face and overcome the challenge of distorted anatomy frequently present in this population. Forthcoming studies with a better level of evidence are required to evaluate functionality and differences between surgical techniques.
De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference
Colmenero, Jordi , Tabrizian, Parissa , Pinato, David J. , Rodríguez‐Perálvarez, Manuel , Pascual, Sonia , Senzolo, Marco , Al‐Adra, David , Petrowsky, Henrik , Kutzke, Jade L. , Watt, Kymberly D. , Pinato, David J , Colmenero, Jordi , Bhangui, Prashant , Sapisochín, Gonzalo , Bhoori, Sherrie , Herrero, José Ignacio , Dawson, Laura Ann , Hosni, Ali , Gastaca, Mikel

Mayo Clinic

Transplantation | December 14, 2021 | Volume: 106 | Issue: 1 | Pages: e30-e45

10.1097/tp.0000000000003998 | PMID 34905760 Get It

De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1 of the major causes of late mortality, being the most common cause of death in the second decade after LT. The overall incidence of DNMs is reported to be in the range of 3.1% to 14.4%, and the incidence is 2- to 3-fold higher in transplant recipients than in age- and sex-matched healthy controls. Long-term immunosuppressive therapy, which is the key in maintaining host tolerance and achieving good long-term outcomes, is known to contribute to a higher risk of DNMs. However, the incidence and type of DNM also depends on different risk factors, including patient demographics, cause of the underlying chronic liver disease, behavior (smoking and alcohol abuse), and pre-existing premalignant conditions. The estimated standardized incidence ratio for different DNMs is also variable. The International Liver Transplantation Society–Spanish Society of Liver Transplantation Consensus Conference working group on DNM has summarized and discussed the current available literature on epidemiology, risk factors, management, and survival after DNMs. Recommendations for screening and surveillance for specific tumors, as well as immunosuppression and cancer-specific management in patients with DNM, are summarized.
Prevention and Management of Donor-transmitted Cancer After Liver Transplantation: Guidelines From the ILTS-SETH Consensus Conference
Domínguez-Gil, Beatriz, Moench, Kerstin, Watson, Christopher, Serrano, M. Trinidad, Hibi, Taizo, Asencio, José M., Rosmalen, Marieke Van, Detry, Olivier, Heimbach, Julie, Durand, François, Watson, Christopher J.E. , Domínguez‐Gil, Beatriz , Moench, Kerstin, Watson, Christopher, Serrano, M. Trinidad, Hibi, Taizo, Asencio, José Manuel , Rosmalen, Marieke Van, Detry, Olivier , Heimbach, Julie, Durand, François

Mayo Clinic

Transplantation | December 14, 2021 | Volume: 106 | Issue: 1 | Pages: e12-e29

10.1097/tp.0000000000003995 | PMID 34905759 Get It

As with any other intervention in health, liver transplantation (LT) entails a variety of risks, including donor-transmitted cancers (DTCs). At present, 2%–4% of used deceased organ donors are known to have a current or past history of malignancy. The frequency of DTCs is consistently reported at 3–6 cases per 10 000 solid organ transplants, with a similar frequency in the LT setting. A majority of DTCs are occult cancers unknown in the donor at the time of transplantation. Most DTCs are diagnosed within 2 y after LT and are associated with a 51% probability of survival at 2 y following diagnosis. The probability of death is greatest for DTCs that have already metastasized at the time of diagnosis. The International Liver Transplantation Society-Sociedad Española de Trasplante Hepático working group on DTC has provided guidance on how to minimize the occurrence of DTCs while avoiding the unnecessary loss of livers for transplantation both in deceased and living donor LT. The group endorses the Council of Europe classification of risk of transmission of cancer from donor to recipient (minimal, low to intermediate, high, and unacceptable), classifies a range of malignancies in the liver donor into these 4 categories, and recommends when to consider LT, mindful of the risk of DTCs, and the clinical condition of patients on the waiting list. We further provide recommendations to professionals who identify DTC events, stressing the need to immediately alert all stakeholders concerned, so a coordinated investigation and management can be initiated; decisions on retransplantation should be made on a case-by-case basis with a multidisciplinary approach.